AU2020305979B2 - Method for treating idiopathic pulmonary fibrosis - Google Patents

Method for treating idiopathic pulmonary fibrosis

Info

Publication number
AU2020305979B2
AU2020305979B2 AU2020305979A AU2020305979A AU2020305979B2 AU 2020305979 B2 AU2020305979 B2 AU 2020305979B2 AU 2020305979 A AU2020305979 A AU 2020305979A AU 2020305979 A AU2020305979 A AU 2020305979A AU 2020305979 B2 AU2020305979 B2 AU 2020305979B2
Authority
AU
Australia
Prior art keywords
days
compound
administered
solvate
polymorph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020305979A
Other languages
English (en)
Other versions
AU2020305979A1 (en
Inventor
Yuanyuan JIANG
Jing Li
Weina LIU
Yanan Liu
Hongjun Wang
Jing Zhao
Yanping Zhao
Weiting ZHONG
Liying Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tide Pharmaceutical Co Ltd
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of AU2020305979A1 publication Critical patent/AU2020305979A1/en
Application granted granted Critical
Publication of AU2020305979B2 publication Critical patent/AU2020305979B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2020305979A 2019-06-25 2020-06-24 Method for treating idiopathic pulmonary fibrosis Active AU2020305979B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/092675 2019-06-25
CN2019092675 2019-06-25
PCT/CN2020/097881 WO2020259528A1 (zh) 2019-06-25 2020-06-24 治疗特发性肺纤维化的方法

Publications (2)

Publication Number Publication Date
AU2020305979A1 AU2020305979A1 (en) 2022-02-17
AU2020305979B2 true AU2020305979B2 (en) 2026-04-23

Family

ID=74061495

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020305979A Active AU2020305979B2 (en) 2019-06-25 2020-06-24 Method for treating idiopathic pulmonary fibrosis

Country Status (10)

Country Link
US (1) US12582653B2 (cg-RX-API-DMAC7.html)
EP (1) EP3992183B1 (cg-RX-API-DMAC7.html)
JP (1) JP7615061B2 (cg-RX-API-DMAC7.html)
CN (2) CN114026072A (cg-RX-API-DMAC7.html)
AU (1) AU2020305979B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021026214A2 (cg-RX-API-DMAC7.html)
CA (1) CA3144113A1 (cg-RX-API-DMAC7.html)
IL (1) IL289192B1 (cg-RX-API-DMAC7.html)
TW (1) TWI804743B (cg-RX-API-DMAC7.html)
WO (1) WO2020259528A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118772118A (zh) * 2020-08-31 2024-10-15 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂的盐、其固体形式及其制备方法和用途
CA3209240A1 (en) * 2021-02-22 2022-08-25 Samuel D. Waksal Rock2 inhibitor for the treatment of viral infection
NO346587B1 (en) * 2021-06-02 2022-10-17 Axichem Ab Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis
TW202327608A (zh) * 2021-09-17 2023-07-16 北京泰德製藥股份有限公司 治療病毒感染的方法
CA3231781A1 (en) * 2021-09-18 2023-03-23 Beijing Tide Pharmaceutical Co., Ltd. Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereof
EP4434513A4 (en) * 2021-11-16 2025-11-19 Beijing Tide Pharmaceutical Co Ltd NANOCRYSTALLINE PREPARATION OF ROCK2 INHIBITOR AND ITS PREPARATION PROCESS
US20250074908A1 (en) * 2022-01-13 2025-03-06 Wuhan Createrna Science And Technology Co., Ltd. Salt of rock inhibitor, crystal form of salt, composition, and pharmaceutical use
TW202423441A (zh) * 2022-10-13 2024-06-16 大陸商北京泰德製藥股份有限公司 治療塵肺病的方法
WO2025017500A1 (en) 2023-07-17 2025-01-23 Graviton Bioscience Bv Formulations of rock2 inhibitors for cns disorders
AU2024292342A1 (en) 2023-07-17 2026-02-26 Graviton Bioscience Bv Formulations and uses of rock2 inhibitors for als
IL327381A (en) 2023-09-28 2026-05-01 Graviton Pharmaceuticals B V Treatment for type 1 diabetes using ROCK2 and DYRK1 inhibitors
IL327385A (en) 2023-09-29 2026-05-01 Graviton Pharmaceuticals B V ROCK2 inhibitors in the treatment of obesity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019000682A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
WO2019001572A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho 相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018506571A (ja) 2015-02-27 2018-03-08 リセラ・コーポレイションLycera Corporation Rho関連プロテインキナーゼの阻害及び疾患の治療のためのインダゾリルチアジアゾールアミン及び関連する化合物
TWI800498B (zh) * 2016-12-21 2023-05-01 義大利商吉斯藥品公司 作為Rho-激酶抑制劑之雙環二氫嘧啶-羧醯胺衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019000682A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
WO2019001572A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho 相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途

Also Published As

Publication number Publication date
WO2020259528A1 (zh) 2020-12-30
JP7615061B2 (ja) 2025-01-16
EP3992183B1 (en) 2026-07-15
JP2022539329A (ja) 2022-09-08
US20220233538A1 (en) 2022-07-28
EP3992183A4 (en) 2023-06-21
US12582653B2 (en) 2026-03-24
IL289192A (en) 2022-02-01
CN114026072A (zh) 2022-02-08
KR20220029681A (ko) 2022-03-08
IL289192B1 (en) 2026-05-01
TWI804743B (zh) 2023-06-11
EP3992183A1 (en) 2022-05-04
AU2020305979A1 (en) 2022-02-17
TW202114679A (zh) 2021-04-16
BR112021026214A2 (pt) 2022-02-15
CN119868365A (zh) 2025-04-25
CA3144113A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
US12582653B2 (en) Method for treating idiopathic pulmonary fibrosis
AU2020230574B2 (en) Method for treating fatty liver disease and/or steatohepatitis
JP2016503003A (ja) ナンセンス突然変異抑制剤としてのピリミド[4,5−b]キノリン−4,5(3h,10h)−ジオン
JP2018138609A (ja) ナフチリジンジオン誘導体
JP2013508412A (ja) mGluR4アロステリック増強剤、組成物、および神経機能不全を治療する方法
WO2022010948A1 (en) Novel cell metabolism modulating compounds and uses thereof for the treatment of viral diseases
JP6560257B2 (ja) ピリミド[4,5−b]キノリン−4,5(3H,10H)−ジオン誘導体
JP7803924B2 (ja) 造血幹細胞移植によって引き起こされる移植片対宿主病を治療する方法
EP3960179B1 (en) Method for treating cough by using diaminopyrimidine compound
WO2024050434A1 (en) ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES
HK40064686A (en) Method for treating idiopathic pulmonary fibrosis
EP4175647A1 (en) Antiviral use of fabp4 modulating compounds
EP4591863A1 (en) Method for treating pneumoconiosis
HK40063173A (en) Method for treating idiopathic pulmonary fibrosis
HK40086216A (en) Method for treating graft versus host disease caused by hematopoietic stem cell transplantation
JP2025529076A (ja) AhR媒介疾患の治療に使用するタピナロおよびそのアナログ製剤
HK40121343A (en) Method for treating idiopathic pulmonary fibrosis
HK40062124B (en) Method for treating cough by using diaminopyrimidine compound
HK40058942A (en) Method for treating fatty liver disease and/or steatohepatitis